RESULTS ROUND-UP: Hologic, Thermo and Varian on the up, Qiagen falls short
This article was originally published in Clinica
Executive Summary
Hologic’s turnaround is “well underway,” as the firm beat analyst expectations for both revenues and earnings during its first quarter, according to Jefferies analyst Raj Denhoy. Q1 sales of $652.8m increased 7% year-on-year and were $20m above analyst consensus; while adjusted earnings of $0.39 per share beat their predictions of $0.36 per share.